Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China

NCT04326374 is registered in ClinicalTrials.gov with Visen Pharmaceuticals (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT04326374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04326374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China
Lead sponsor
Visen Pharmaceuticals (Shanghai) Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 30, 2019
Completion date
April 30, 2022
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, growth hormone deficiency, hormones, pituitary disease, anterior, pituitary diseases